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Understanding the variables that influence microbiome studies is critical for successful translational 
research. Inflammatory bowel disease (IBD) is a complex group of diseases that can present at multiple 
locations within the Gastrointestinal tract. Here, using the FAMISHED study cohort, we aimed to 
investigate the relationship between IBD condition, IBD disease location, and the microbiome. 
Signatures of the microbiome, including measures of diversity, taxonomy, and functionality, all 
significantly differed across the three different IBD conditions, Crohn’s disease (CD), ulcerative colitis 
(UC), and microscopic colitis (MC). Notably, when stratifying by disease location, patients with CD in 
the terminal ileum were more similar to healthy controls than patients with CD in the small bowel or 
colon, however no differences were observed at different disease locations across patients with UC. 
Change in taxonomic composition resulted in changes in function, with CD at each disease location, 
UC and MC all having unique functional dysbioses. CD patients in particular had deficiencies in Short-
Chain Fatty Acid (SCFA) pathways. Our results demonstrate the complex relationship between IBD 
and the microbiome and highlight the need for consistent strategies for the stratification of clinical 
cohorts and downstream analysis to ensure results across microbiome studies and clinical trials are 
comparable.
Advances in the microbiome field have led to intense efforts to translate meaningful research into clinical inter-
ventions. To successfully develop therapeutic interventions and perform effective clinical research, effective 
standardisation of the microbiome space is  critical1. There are multiple aspects to the standardisation of the 
microbiome field, with many studies demonstrating the influence of variation across technical steps and the 
need for robust standards and  controls2. An aspect of microbiome studies that is harder to control is how studies 
stratify their patient cohorts, with a range of both unknown and known factors such as environmental variables 
and host-genetics leading to conceptually similar studies having different conclusions on the role of specific 
organisms in  disease3. This picture is even more complex for diseases such as inflammatory bowel disease 
(IBD), where there are multiple conditions which patients can present with and disagreement on how aspects 
of the disease are clinically  classified4. Despite being studied as a focal point for microbiome research for over a 
 decade5, we still do not fully understand how IBD heterogeneity influences the results of microbiome studies or 
how changing the way patients are stratified influences the conclusions of microbiome studies.
Although IBD is often associated with changes in the  microbiome5, questions remain over how disease vari-
ability influences the diversity and composition of the microbiome. Multiple studies have explored the role of 
disease location and severity on taxonomic composition and diversity of the microbiome, however there is no 
consensus and studies often report contrasting results. For example, a recent study showed that patients with 
ileal and ileocolonic disease had significantly decreased microbiome diversity compared to patients with colonic 
 disease6. This expanded on the work of previous studies which had suggested that ileal CD is more notable for its 
microbiome dysbiosis than non-ileal  CD7 and that the microbiome of patients with disease in the ileum deviate 
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most from a healthy microbiome compared to disease located elsewhere in the gastrointestinal  tract8. In contrast 
to this body of work, two recent large metagenomic studies on IBD noted no discernible effect of location on 
the microbiome in their disease cohorts when considering how to group patients for  analysis9,10. Despite not 
observing a difference due to disease location, the latter study did note the influence that disease activity had 
on the  microbiome10. To our knowledge, no study has elucidated whether perceived changes in microbiome 
taxonomic composition and diversity due to disease location leads to changes in microbiome functional poten-
tial. Furthermore, some large microbiome studies still do not consider disease location as a factor which may 
influence their study  conclusions11.
Here, we perform a comprehensive investigation into how microbiome signatures change across the three 
IBD conditions Crohn’s disease (CD), ulcerative colitis (UC), and microscopic colitis (MC), the latter of which 
has often been neglected in IBD studies. Furthermore, we explore the role which disease location has on the 
microbiome and the importance of consistent stratification strategies to ensure the meaningful interpretation 
of results. Finally, we performed functional predictions to understand whether changes in taxonomic signatures 
led to changes in the functional capacity of the microbiome.
Methods
Study population. Patients were recruited as part of the FAMISHED (Food and Fermentation using 
Metagenomics in Health and Disease) study. The study was given approval by the United Kingdom’s NHS Health 
Research Authority and the Warwick Research Ethics Committee ref: 09/H1211/38 and conducted in accord-
ance with the guidance and regulations set out by the United Kingdom’s NHS Health Research Authority. Writ-
ten informed consent was obtained from all participants in the study, with patients under 18 excluded from the 
study.
175 stool samples were collected to include those with CD, UC, and MC (Fig. 1, Supplementary Table 1). 
Conditions were further delineated by disease location; for CD; Small Bowel Crohn’s (CD-SB), Terminal ileitis 
(CD-TI), Colonic Crohn’s (CD-CC), and CD of multiple sites (CD-Multi); for UC; Left-side colitis (UC-LS), 
Pancolitis (UC-PC), and Ulcerative Proctitis (UC-PR) (Fig. 1). Patients and healthy controls were similar in both 




CD (All) 30 60/40 52.8 ± 14.2s
CD-CC 16 50/50 50.5 ± 11.7
CD-SB 6 50/50 61.7  ± 10.8
CD-TI 7 43/57 51.3  ± 20.8
CD-Multi 1 100/0 47 ± 0
UC (All) 56 60/40 53.4  ± 15.7
UC-LS 23 61/39 56.9  ± 15.9
UC-Pan 13 85/15 46.9 ± 16.0
UC-Proc 20 45/55 53.6 ± 14.5
MC (All) 5 20/80 66.2 ± 16.7




Figure 1.  (A) Overview of FAMISHED Patient cohort. (B) NMDS ordination plot based on the Bray Curtis 
dissimilarity between Healthy Controls and three IBD conditions, CD, MC, UC. (C) The Observed ASV 
diversity of Healthy Controls and patients classified as having IBD. (D) The Observed ASV diversity of Healthy 
Controls and patients classified as having CD, UC, and MC. (E) The Observed ASV diversity of Healthy 
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age and sex composition (Fig. 1). Antibiotic usage in the past month was recorded, with no antibiotics being 
recorded for usage in the CD cohort and only one incidence in the UC cohort. No significant difference was 
observed between those patients with prior surgery and those without.
We utilised clinical scoring systems related to IBD in assessing the severity of the disease. For CD patients 
the Harvey-Bradshaw index (HBI) score was calculated and for UC patients the Partial Mayo Score (PMS) was 
calculated. Scores were grouped as Inactive (< 5 HBI, < 1 PMS), Mild (5–7 HBI, 2–4 PMS), Medium (8–16 HBI, 
5–6 PMS), or Severe (> 16 HBI, 7 – 9 PMS)12,13. We further looked into the duration of disease of the recruited 
patients in the study. We estimated this by subtracting the time between dates when the diagnosis was first made 
and the dates of when the samples were collected for the study. The mean durations for MC, UC and CD were 
2.3 years, 4.6 years and 5.7 years respectively.
Patient and public involvement. Patients were involved in the design and dissemination of FAMISHED study 
where elements of the study were presented to the patient research advisory group. Specifically, dissemination 
in both scientific and lay literature were encouraged. The latter was undertaken via newsletters overseen by 
Research & Development Office.
DNA extractions and sequencing. DNA was extracted from stool according to the Earth Microbiome 
Protocol using the Qiagen PowerSoil  Kit14. PCR amplicons were generated using Platinum Taq polymerase (Inv-
itrogen) for the V4 16S region 515F(Parada)/806R(Apprill) and sequenced using a NextSeq 550 High Output 
v2.5 kit producing > 100,000 paired-end reads per  sample15,16.
Bioinformatics. Sequenced data was analysed through the QIIME2 (version 2019.7) with Deblur used for 
sequence quality control using the same settings as previously described by the UK National Institute for Biologi-
cal Standards and  Control2,17,18. Following removal of primers and adapters with q2-cutadapt plugin, paired ends 
were joined using the q2-vsearch plugin. Sequences were quality controlled using the q2-quality-filter plugin 
followed by the q2-deblur plugin. The q2-feature-classifier (sklearn) was used to assign taxonomy to repre-
sentative sequences against the Silva database (132 release, https:// www. arb- silva. de/ [last accessed 02/1082019]. 
Sequences were further filtered using the q2-feature-table plugin to ensure all features which were less than 
0.005% abundant for each replicate were removed. The q2-diversity plugin was used to generate rarefaction 
curves, which indicated saturation at approximately 30,000 sequences. Conservatively, we rarefied all samples to 
50,000 sequences and exported the Amplicon Sequence Variant (ASV) final feature table for statistical analysis 
in R version 3.6019. The q2-diversity plugin was also used to calculate the Faith’s Phylogenetic Diversity Meas-
ure for all rarefied samples. We used the tool PICRUSt2 to predict metagenomic functions from the 16S rRNA 
sequencing  data20.
Statistical analysis. All statistical analysis was performed using R (version 3.60). The Faiths Phylogenetic 
Diversity Measure and Observed Number of ASVs were used as measures of alpha diversity across the samples 
and were calculated using the q2-diversity plugin. A Wilcoxon Rank-Sum test was performed to compare the 
mean average of each diversity measure between IBD patients and healthy controls. A Kruskal–Wallis one-way 
analysis of variance was conducted to compare diversity measures across IBD conditions, with a Dunn test con-
ducted using the ‘dunn.test’ package to perform pairwise comparison as a post-hoc test following the Kruskal–
Wallis test with p values corrected for false discovery using the Benjamini–Hochberg procedure. For each IBD 
condition, diversity measures were compared across disease location using a Kruskal–Wallis one-way analysis of 
variance with the Dunn test used to perform a pairwise-comparisons with p values corrected for false discovery 
using the Benjamini–Hochberg procedure. This same method was applied to compare diversity measures for 
different levels of disease severity across IBD conditions. Metadata and the Final Feature table were imported 
into Phyloseq for beta-diversity  analysis21. A Bray–Curtis dissimilarity matrix was constructed and visualized 
following a non-metric multidimensional scaling (NMDS). Comparison of community composition between 
IBD conditions was conducted using a permutational multivariate analysis of variance (PERMANOVA) through 
the package ‘vegan’ using the function ‘adonis’. A pairwise PERMANOVA was used to compare each IBD condi-
tion using the package ‘RVAideMemoire’ with the function ‘pairwise.perm.manova’ with p values corrected for 
false discovery using the Benjamini–Hochberg procedure. This method was repeated to compare community 
composition across disease locations for each IBD disease. The tool LEfSe was used to determine which taxa 
were enriched for each IBD condition and IBD  location22. Data on Metacyc pathway abundance for each sample 
as measured using PICRUSt2 was also analysed using R and LEfSe. Metadata and a table of pathway abun-
dances were imported into Phyloseq for beta-diversity  analysis21. A Bray–Curtis dissimilarity matrix was con-
structed and visualized following a non-metric multidimensional scaling (NMDS). Comparison of community 
composition between IBD conditions was conducted using a permutational multivariate analysis of variance 
(PERMANOVA) through the package ‘vegan’ using the function ‘adonis’. A pairwise PERMANOVA was used 
to compare each IBD condition using the package ‘RVAideMemoire’ with the function ‘pairwise.perm.manova’ 
with p values corrected for false discovery using the Benjamini–Hochberg procedure. The tool LEfSe was used 
to determine which pathways were enriched for each IBD condition and IBD  location22.
Results
Changes in microbiome diversity and composition across patients with IBD. We first wanted 
to establish how gut microbiome diversity and composition changed across patients with CD, UC, and MC. 
Notably, few studies have previously looked at  MC23. We performed a taxonomic analysis of the gut microbiome 
of patients and healthy controls using 16S rRNA sequencing with data processed using Deblur through the 
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QIIME2  platform17,18. The number of observed Amplicon Sequence Variants (ASVs) was used as a measure of 
absolute species diversity across the four study  cohorts24. All IBD patients had significantly less observed spe-
cies diversity than healthy controls (Healthy = 320 ASVs vs IBD = 290 ASVs, p = 0.0276, Fig. 1, Supplementary 
Table 2).
When stratifying patients by IBD condition, results followed a commonly reported pattern with CD patients 
having significantly less observed diversity (ASVs = 248) than both UC patients (ASVs = 319) and healthy controls 
(ASVs = 320) (p < 0.05 in all cases, Fig. 1, Supplementary Table 3). Notably, UC patients had similar observed 
diversity to that of healthy controls (Healthy = 320 ASVs vs UC = 319 ASVs), but the average observed diversity 
of the gut microbiome of MC patients (ASVS = 259) was similar to that of CD patients (ASVs = 248). To assess 
whether observed diversity reflected a change in phylogenetic diversity, we used the Faith PD  measure25. Results 
widely followed the pattern reported for Observed ASVs with fewer species leading to less phylogenetic diver-
sity (Supplementary Figure 11). IBD patients had a significantly less phylogenetically diverse microbiome than 
healthy controls (p = 0.0459). When stratifying by IBD condition, CD patients had significantly less phylogenetic 
diversity in their microbiomes than both healthy controls and UC patients (p < 0.05 in all cases, Supplementary 
Table 4). Whereas MC patients and CD patients had microbiomes with similar levels of phylogenetic diversity.
We next investigated how changes in alpha diversity were reflected in similarity of taxonomic composition 
changes between IBD conditions using the Bray–Curtis dissimilarity measure (Fig. 1). There were significant 
differences in the taxonomic composition of the microbiome between healthy controls, CD, UC, and MC patients 
(PERMANOVA,  R2 = 0.02845, p < 0.001). Furthermore, pairwise comparison demonstrated both CD and UC 
patients had significantly different taxonomic compositions relative to healthy controls and that UC and CD 
patients had significantly different taxonomic compositions from one another (PERMANOVA, p < 0.01, Sup-
plementary Table 5).
The impact of disease location on the microbiome. To understand how disease location influenced 
the microbiome, we stratified patients according to where CD or UC presented. Not enough patients were 
recruited for MC to do this, owing to the rarity of the condition. For patients with CD, there were significant 
differences in measures of alpha diversity according to where the disease presented (p < 0.001 in all cases, Fig. 1, 
Supplementary Tables 6 and 7). CD-CC and CD-SB, was associated with significantly lower level of observed 
(229 and 230 ASVs for CD-CC and CD-SB respectively) and phylogenetic diversity (16.67 Faith PD, 16.88 Faith 
PD for CD-CC and CD-SB respectively) than CD-TI (309 ASVs, 21 Faith PD, p < 0.05 in all cases), with CD-TI 
indistinguishable in diversity measures from healthy controls. These differences were also reflected in compo-
sition analysis; patients with CD-TI did not have a significantly different taxonomic composition to healthy 
controls, however, patients with CD-CC and CD-SB did have significantly different taxonomic compositions 
compared to healthy controls (Supplementary Figure 1, Supplementary Table 8).
Unlike CD, when investigating disease location for UC, none of the UC locations were significantly different 
in microbiome diversity or composition from one another, or from that of the healthy controls (Fig. 1, Supple-
mentary Tables 8, 9 and 10). When comparing CD-TI, CD-CC, and CD-SB, with the different locations of UC, 
CD groups that were significantly different from healthy controls (CD-CC and CD-SB) were also significantly 
different in composition from multiple UC locations (Fig. 1E, Supplementary Figure 1C and Supplementary 
Figure 1D).
We next investigated the influence that disease severity had on the microbiome. No significant difference 
was observed between those patients with prior surgery (e.g., resection) and those without, though this may 
be due to the limited number of patients who had a history of surgery. This was both at the individual disease 
level (e.g., CD, UC, or MC) as well as the higher disease classification level of IBD. The current cohort had an 
over-representation of patients with mild disease and only a limited number of patients with moderate or severe 
disease. When stratifying CD patients by severity, for CD there were only two reported cases of moderate disease 
and no cases of severe disease. Across CD patients there was no significant differences in Faith or Observed ASV 
diversity across our patient cohort (Observed ASV diversity Kruskal Wallis Chi Square = 1.7866 p = 0.4093, Faith 
PD Kruskal Wallis Chi Square = 1.585, p = 0.4557). Clearly, more patients of a higher disease severity are needed 
to elucidate the interplay between disease severity and the microbiome in CD patients. However, these finding 
do confirm that the results observed for disease location is not due to a confounding issue of disease severity. 
Mirroring the CD cohort, for UC patients, there was no significant relationship between the microbiome and 
severity of disease for this cohort (Observed ASV diversity Kruskal Wallis Chi Square = 3.6606, p = 0.4539, Faith 
PD Kruskal Wallis Chi Square = 4.6736, p = 0.3225), however, further work is needed with more representation 
from moderate and severe disease to elucidate the relationship between the microbiome and IBD disease sever-
ity levels.
Different IBD conditions and locations have different taxonomic markers. Previous studies have 
highlighted a decrease in the families Lachnospiraceae and Ruminococcaceae during IBD whereas facultative 
anaerobes such as the Proteobacteria are increased compared to healthy  controls5,7,26,27. Across IBD conditions, 
microbial imbalances have been observed at multiple different taxonomic levels with many groups of bacte-
ria co-occurring across  patients28. Using the tool  LEfSe22, we determined which microbial groups most likely 
explained the observed differences in microbiome composition.
When comparing the microbiome of CD patients to healthy controls there was a significant decrease in the 
abundance of several key phyla such as the Actinobacteria, Bacteroidetes, Tenericutes, and Firmicutes (LDA 
(log10) > 2.0, p < 0.05 in all cases, Fig. 2, Supplementary Table 12) as has been reported in prior  studies19. In par-
ticular, the genera Faecalibacterium, Alistipes, Eubacterium and Ruminococcus were significantly decreased in CD 
patients relative to healthy controls demonstrating a reduction in obligate anaerobes. Furthermore, there was a 
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clear enrichment in CD patients for facultative anaerobic bacteria such as the phyla Bacilli and Proteobacteria. 
At the genus level Streptococcus, Burkholderia and Actinetobacter were significantly enriched relative to healthy 
controls, suggesting an enrichment of opportunistic pathogens in CD (LDA (log10) > 2.0, p < 0.05).
When stratifying CD by disease location, several taxa significantly differed between individual disease loca-
tions and healthy controls (Fig. 2, Supplementary Table 13). CD-TI was significantly enriched for Faecalibacte-
rium relative to other CD conditions and had multiple taxa usually characteristic of a healthy gut enriched relative 
to other CD disease locations (LDA (log10) > 3.0, p < 0.05, Supplementary Table 13). Only CD-CC and CD-SB 
were enriched for opportunistic pathogens with CD-CC patients enriched for Streptococcus and Burkholderia 
relative to all other disease locations and healthy controls, and CD-SB enriched for Escherichia and Acinetobacter 
relative to all other disease locations and healthy controls (LDA (log10) > 2.0, p < 0.05, Supplementary Table 13). 
Although enrichment of Escherichia coli and reduction in Faecalibacterium is a well-established signature of 
 CD7–9, data here demonstrates this only applies to certain subsets of CD such as CD-CC and CD-SB, with clear 
differences in the taxa present between CD-TI and CD-CC and CD-SB.
Despite having no clear changes in alpha diversity, the microbiome of UC patients had several taxa important 
for human health enriched or decreased compared to healthy controls supporting the demonstrated changes in 
compositional analysis (Fig. 3, Supplementary Table 14). Although there were clear enrichments for opportun-
istic pathogens such as Actinetobacter, obligate anaerobes including Blautia, Eubacterium and Collinsella, were 
enriched in UC relative to healthy controls suggesting a complex dysbiosis unlike that of CD (LDA (log10) > 2.0, 
p < 0.05 in all cases, Supplementary Table 14). Important taxonomic signatures of CD such as a reduction in 
Faecalibacterium and enrichment in Escherichia relative to healthy controls were not found in UC patients sup-
porting our composition and diversity data that UC and CD patients have different dysbiosis, as well as work 
by studies  prior7,8. Indeed, when comparing CD and UC directly, there were over 30 taxa significantly differ-
entially abundant between the two conditions with an LDA score of > 2.0 (Supplementary Table 15). Relative 
to the microbiome of CD patients, UC patients were enriched for obligate anaerobes such as Actinobacteria, 
Rumonococcacae, Erysipelotrichiae, with CD being enriched for the Proteobacteria family Pasteurellaceae relative 
to UC. There were no taxa which differed across disease locations for UC, supporting the finding that there were 





Figure 2.  (A) Cladogram demonstrating taxa which are enriched in each patient group when comparing 
Healthy Controls and CD patients. (B) Cladogram demonstrating taxa which are enriched in each patient group 
when comparing Healthy Controls and CD patients when accounting for disease location. (C) Changes in 
metabolic pathways between Healthy Controls and CD Patients. (D) Changes in metabolic pathways between 
Healthy Controls and CD patients when accounting for disease location.
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taxa were observed when accounting for disease severity of UC or CD, though this could be due to a low sample 
numbers of moderate and severe disease.
A
B
Figure 3.  (A) Cladogram demonstrating taxa which are enriched for UC or Healthy Controls. (B) Changes in 
metabolic pathways between healthy volunteers and UC patients.
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For MC the main distinguishing family was the Rikinellaceae, with Alistipes significantly enriched in MC 
patients relative to Healthy Controls (p < 0.05, Supplementary Table 16). We found no evidence of Akkermansia 
being decreased in MC patients as previously  described23,29, though the low sample number in the MC cohort 
could be a reason for this.
Taxonomic changes leads to microbiomes of differing functional capacities. Combined, our 
diversity, composition, and taxonomic data demonstrate that the microbiome changes IBD conditions and in 
the case of CD, can be different for the same condition at different GI locations. We next wanted to understand 
how these observed changes impact the functionality of the microbiome, with a particular focus on molecules 
important for colonocyte health and immunomodulation, such as short-chain fatty acids (SCFAs) and bile-
acids30–32. We used the tool PiCRUSt2 to develop predicted metagenomes based on 16S rRNA sequencing  data20.
There were significant differences in the composition of functional pathways in the gut microbiome between 
different IBD conditions (p > 0.05 in all cases, Supplementary Table 17). We identified 71 pathways that were 
differentially abundant between microbiome of patients with CD and healthy controls (Fig. 2, Supplementary 
Table 18). CD patients had a decreased abundance of multiple pathways responsible for the generation and trans-
formation of propionate and butyrate. Specifically, CD patients had significantly reduced abundance in pathways 
for the generation of propionate and butyrate from carbohydrate degradation, including the pathways, pyruvate 
to propionate (P108_PWY), acetyl-CoA to butyrate (PWY_5677), succinate to butyrate (PWY_5676), and pro-
panediol degradation to propionate (PWY_7013). CD patients were also reduced in amino-acid metabolism to 
butyrate (PWY_163). Loss of SCFAs was coupled with the microbiome having reduced capacity for vitamin  K2 
production (PWY_5896, POLYAMINSYN3_PWY, PWY_6263, PWY_5850, PWY_5845), a microbially derived 
nutrient important for  healing33. As well as the reduction in pathways which produce molecules critical for the 
host’s health, the gut microbiome of CD patients was increased in pathways for the degradation of aromatic 
compounds (CATECHOL.ORTHO.CLEAVAGE.PWY) including salicylate (PWY.6182) which is often used for 
the treatment of CD and  UC34. An increase in antimicrobial resistance genes (beta-lactam) was also observed 
(PWY_6470), perhaps due to the associated increase of opportunistic pathogens.
When stratifying by disease location, although CD-TI was similar taxonomic diversity and composition to 
healthy controls, all CD disease locations had a significant reduction relative to healthy controls in the path-
ways responsible for butyrate production from both acetyl-CoA fermentation (PWY_5676) and amino acid 
fermentation (P163_PWY). This suggests some functional redundancy. Despite this, all specific locations had 
unique profiles for metabolic pathways. CD-TI patients were enriched for pyruvate to butyrate fermentation 
(CENTFERM_PWY) relative to CD-SB and CD-CC. CD-SB was enriched for succinate fermentation to butyrate 
relative to CD-CC and CD-TI (PWY.5677), and only CD-CC patients were enriched for beta-lactam resistance 
(PWU_6470) and menaquinol (vitamin  K2) production. This data illustrates that although CD patients are defi-
cient in several key pathways relative to healthy controls, when grouping patients by site-specific location, the 
dynamics are more complex with each specific site of CD having its own functional deficiency.
UC patients were deficient for the key SCFA pyruvate to propionate pathway (P108.PWY), with an increase 
in UC patients for the pyruvate to isobutanol pathway (PWY.7111) (Fig. 3, Supplementary Table 19). Unlike CD 
patients, UC patients had no clear deficiencies in butyrate pathways compared to the healthy controls, nor did 
they have any evidence for deficiency in pathways involved in butyrate production or aromatic degradation. This 
demonstrates that the taxonomic differences observed between UC and CD patients resulted in different microbi-
ome functionality, with UC having reduced SCFA relative to healthy controls but not to the extent of CD patients.
For MC patients, healthy controls were enriched for fermentation to acetone, of which many genes are com-
mon with SCFA pathways, such as the production of acetoacetyl-CoA (Fig. 3, Supplementary Table 21). However, 
other than this, there were no clear reduction in the metabolic function of the microbiome for MC patients 
(Fig. 3), with more patient samples likely needed to explore function in the MC cohort further.
Discussion
The role of the microbiome is linked to both the causation and progression of  IBD5. As our understanding of 
the microbiome has increased, it has become clear that observations based on a cohort level do not satisfacto-
rily capture the subtle dynamics underlying this complex group of diseases. This has led to a number of studies 
publishing results which contradict one-another in both the key taxa present and the factors that could con-
tribute to  disease3–11. Here, we aimed to understand what the microbiome taxonomic and functional signatures 
were across three unique IBD conditions and at different locations of disease presentation. This was in order to 
increase our knowledge of the complex dynamics of the microbiome in IBD and to highlight how the strategies 
by which studies are stratified can influence our understanding and interpretation of the microbiome in patients 
with IBD. From the data and analysis collected in this study, we demonstrate that when analysing IBD at a high 
level classification, the role of the microbiome in Crohn’s disease, ulcerative colitis, and microscopic colitis, are 
vastly different given their different compositions, taxonomic markers, and functional capacity. Depending on 
whether we analysed data as IBD versus Healthy, stratified by IBD Condition (CD vs MC vs UC), or stratified 
by IBD condition and location, conclusions on microbiome diversity, composition, and function significantly 
changed. Importantly, this means different studies analysing IBD that have differences in stratification strate-
gies will produce different results owing to the different signatures present across conditions, and in the case of 
CD, across different disease locations. For some studies, results inferred at a cohort-wide level, potentially will 
not apply to subsets of the IBD population. This has important implications for both therapeutic and diagnostic 
design and validation.
Our observed changes in microbiome taxonomic composition and diversity were widely reflected in predic-
tions of functional capacity. Whilst marker based metagenomic inference has limitations in relation to direct 
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metagenomic sequencing, with increasing numbers of publicly available genomes and improvements in the 
resolution of 16S rRNA sequencing through ASV approaches, the accuracy of this approach has improved, and 
it does allow us to explore potential differences which are present due to changes in taxonomic  composition20. 
Using this approach, it was clear that the microbiomes of the three disease conditions, and of the three CD 
locations, all had unique dysbioses with some unifying themes. For example, all CD patients were observed to 
be significantly deficient in pathways for the production of SCFAs that have a myriad of important functions 
relating to immune function and gut  health35–41. SCFAs are imperative to intestinal homeostasis: providing a key 
energy source for colonocytes, maintenance of hypoxia, production of antimicrobial compounds, and promo-
tion of anti-inflammatory  cytokines35–41. The loss of the ability to produce SFCAs by the gut microbiome in CD 
patients could lead to inflammation and reduced cellular membrane integrity giving a mechanism for disease.
In this study, most patients had mild disease and as such we did not detect any differences between the 
microbiome and disease severity as previously  reported10. Future work is needed to understand whether these 
patterns hold for patients with more progressed disease and the way that disease severity changes the microbiome 
for different IBD conditions and disease locations.
In conclusion, this study suggests the microbiome does not uniformly present in the same way for all IBD 
conditions and that the microbiome can even present differently for the same disease at a different GI location. 
Results here highlight the importance of understanding the different factors than can influence the results of 
microbiome studies. Consistent stratification of clinical cohorts used in microbiome studies is required to ensure 
the meaningful comparison of microbiome studies and clinical trials.
Data availability
All raw sequences used in this study have been deposited in the NCBI Sequence Research Archive 
(PRJNA761255).
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